Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future

Lasers in Medical Science

Volumn 30, Issue 9, 2015, Pages 2381-2387

  Marchal, Sophie ^a,b,c   Dolivet, Gilles ^a,b,c   Lassalle, Henri Pierre ^a,b,c   Guillemin, François ^a,b,c   Bezdetnaya, Lina ^a,b,c  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^c Service d'anatomie pathologique Institut de cancérologie de Lorraine   (France)

Author keywords

Active targeting; Head and neck squamous cell carcinoma; Nanoparticles; Passive targeting; Photodynamic therapy

Indexed keywords

ANTIBODY CONJUGATE; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOCARRIER; OXYGEN; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE;

ARTICLE; CLINICAL PRACTICE; DISEASE ERADICATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIGHT; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; THERAPY EFFECT; ANIMAL; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; MOLECULARLY TARGETED THERAPY; PHOTOCHEMOTHERAPY; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; PHOTOCHEMOTHERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84948387091     PISSN: 02688921     EISSN: 1435604X     Source Type: Journal    
DOI: 10.1007/s10103-014-1703-4     Document Type: Article

References (55)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371:1695–1709
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
3. Agostinis P, Berg K, Cengel KA et al (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61:250–281
4. Bredell MG, Besic E, Maake C, Walt H (2010) The application and challenges of clinical PD-PDT in the head and neck region: a short review. J Photochem Photobiol B 101:185–190
5. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28
6. Reuther T, Kubler AC, Zillmann U et al (2001) Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. Lasers Surg Med 29:314–322
7. Biel MA (2010) Photodynamic therapy of head and neck cancers. Methods Mol Biol 635:281–293
8. Schweitzer VG, Somers ML (2010) PHOTOFRIN-mediated photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx. Lasers Surg Med 42:1–8
9. de Visscher SA, Dijkstra PU, Tan IB et al (2013) mTHPC mediated photodynamic therapy (PDT) of squamous cell carcinoma in the head and neck: a systematic review. Oral Oncol 49:192–210
10. Jerjes W, Upile T, Hamdoon Z et al (2011) Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma. Lasers Surg Med 43:463–469
11. Karakullukcu B, Stoker SD, Wildeman AP et al (2013) A matched cohort comparison of mTHPC-mediated photodynamic therapy and trans-oral surgery of early stage oral cavity squamous cell cancer. Eur Arch Otorhinolaryngol 270:1093–1097
12. Tan IB, Dolivet G, Ceruse P et al (2010) Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study. Head Neck 32:1597–1604
13. Jerjes W, Upile T, Akram S, Hopper C (2010) The surgical palliation of advanced head and neck cancer using photodynamic therapy. Clin Oncol (R Coll Radiol) 22:785–791
14. Karakullukcu B, Nyst HJ, van Veen RL et al (2012) mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: development of a new method. Head Neck 34:1597–1606
15. Berg K, Folini M, Prasmickaite L et al (2007) Photochemical internalization: a new tool for drug delivery. Curr Pharm Biotechnol 8:362–372
16. Berg K, Nordstrand S, Selbo PK et al (2011) Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization. Photochem Photobiol Sci 10:1637–1651
17. Morrison SA, Hill SL, Rogers GS, Graham RA (2014) Efficacy and safety of continuous low-irradiance photodynamic therapy in the treatment of chest wall progression of breast cancer. J Surg Res 192:235–241
18. Wang HW, Rickter E, Yuan M et al (2007) Effect of photosensitizer dose on fluence rate responses to photodynamic therapy. Photochem Photobiol 83:1040–1048
19. Henderson BW, Gollnick SO, Snyder JW et al (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64:2120–2126
20. Garrier J, Bressenot A, Grafe S et al (2010) Compartmental targeting for mTHPC-based photodynamic treatment in vivo: correlation of efficiency, pharmacokinetics, and regional distribution of apoptosis. Int J Radiat Oncol Biol Phys 78:563–571
21. Bugaj AM (2011) Targeted photodynamic therapy—a promising strategy of tumor treatment. Photochem Photobiol Sci 10:1097–1109
22. Lim CK, Heo J, Shin S et al (2013) Nanophotosensitizers toward advanced photodynamic therapy of cancer. Cancer Lett 334:176–187
23. Master A, Livingston M, Sen Gupta A (2013) Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release 168:88–102
24. Ernsting MJ, Murakami M, Roy A, Li SD (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782–794
25. Buchholz J, Wergin M, Walt H et al (2007) Photodynamic therapy of feline cutaneous squamous cell carcinoma using a newly developed liposomal photosensitizer: preliminary results concerning drug safety and efficacy. J Vet Intern Med 21:770–775
26. Buchholz J, Kaser-Hotz B, Khan T et al (2005) Optimizing photodynamic therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Clin Cancer Res 11:7538–7544
27. de Visscher SA, Kascakova S, de Bruijn HS et al (2011) Fluorescence localization and kinetics of mTHPC and liposomal formulations of mTHPC in the window-chamber tumor model. Lasers Surg Med 43:528–536
28. Lassalle HP, Dumas D, Grafe S et al (2009) Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPC. J Control Release 134:118–124
29. Bovis MJ, Woodhams JH, Loizidou M et al (2012) Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy. J Control Release 157:196–205
30. Igarashi A, Konno H, Tanaka T et al (2003) Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer. Toxicol Lett 145:133–141
31. Hofman JW, Carstens MG, van Zeeland F et al (2008) Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation. Pharm Res 25:2065–2073
32. Low K, Knobloch T, Wagner S et al (2011) Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells. Nanotechnology 22:245102
33. Rojnik M, Kocbek P, Moret F et al (2012) In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy. Nanomedicine (Lond) 7:663–677
34. Lee SJ, Park K, Oh YK et al (2009) Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials 30:2929–2939
35. Yang PW, Hung MC, Hsieh CY et al (2012) The effects of photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers Med Sci 28:605–614
36. Martinez-Carpio PA, Trelles MA (2010) The role of epidermal growth factor receptor in photodynamic therapy: a review of the literature and proposal for future investigation. Lasers Med Sci 25:767–771
37. Edmonds C, Hagan S, Gallagher-Colombo SM et al (2012) Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: targeting survival pathways to increase PDT efficacy in ovarian and lung cancer. Cancer Biol Ther 13:1463–1470
38. Jin CS, Zheng G (2011) Liposomal nanostructures for photosensitizer delivery. Lasers Surg Med 43:734–748
39. Gijsens A, Missiaen L, Merlevede W, de Witte P (2000) Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 60:2197–2202
40. Hemming AW, Davis NL, Dubois B et al (1993) Photodynamic therapy of squamous cell carcinoma. An evaluation of a new photosensitizing agent, benzoporphyrin derivative and new photoimmunoconjugate. Surg Oncol 2:187–196
41. Kameyama N, Matsuda S, Itano O et al (2011) Photodynamic therapy using an anti-EGF receptor antibody complexed with verteporfin nanoparticles: a proof of concept study. Cancer Biother Radiopharm 26:697–704
42. Master A, Malamas A, Solanki R et al (2013) A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. Mol Pharm 10:1988–1997
43. Christopoulos A, Ahn SM, Klein JD, Kim S (2011) Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis. Head Neck 33:1220–1229
44. Dabkeviciene D, Sasnauskiene A, Leman E et al (2012) mTHPC-mediated photodynamic treatment up-regulates the cytokines VEGF and IL-1alpha. Photochem Photobiol 88:432–439
45. Solban N, Selbo PK, Sinha AK et al (2006) Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 66:5633–5640
46. Bhuvaneswari R, Yuen GY, Chee SK, Olivo M (2011) Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model. Lasers Surg Med 43:651–662
47. Ferrario A, Gomer CJ (2006) Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 25:251–259
48. Uehara M, Ikeda H, Nonaka M et al (2011) Predictive factor for photodynamic therapy effects on oral squamous cell carcinoma and oral epithelial dysplasia. Arch Oral Biol 56:1366–1372
49. Zheng G, Chen J, Stefflova K et al (2007) Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A 104:8989–8994
50. Rai P, Mallidi S, Zheng X et al (2010) Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev 62:1094–1124
51. Reddy GR, Bhojani MS, McConville P et al (2006) Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 12:6677–6686
52. Li Z, Wang C, Cheng L et al (2013) PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy. Biomaterials 34:9160–9170
53. Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141
54. Senge MO, Brandt JC (2011) Temoporfin (Foscan(R), 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)—a second-generation photosensitizer. Photochem Photobiol 87:1240–1296
55. Rigual NR, Shafirstein G, Frustino J et al (2013) Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol Head Neck Surg 139:706–711